Early Institution of Mechanical Support Improves Outcomes in Primary Cardiac Allograft Failure

Marasco, Silvana; Esmore, Donald S.; Negri, Justin; Rowland, Michael; Newcomb, Andrew; Rosenfeldt, Franklin; Bailey, Michael; Richardson, Meroula

doi:10.1016/j.healun.2005.06.007

Cited by 100 publications

(88 citation statements)

References 11 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[226][227][228][229][230][231][232][233][234][235] The majority of published data describe the relatively successful use of extracorporeal membrane oxygenation (ECMO) in cases of primary graft failure. Although 30-day mortality is reduced in those who receive ECMO, in those who survive 30 days, long-term survival appears to be comparable to those who do not have primary graft failure.…”

Section: Mechanical Circulatory Support In Amr With Hemodynamic Comprmentioning

confidence: 99%

“…Although 30-day mortality is reduced in those who receive ECMO, in those who survive 30 days, long-term survival appears to be comparable to those who do not have primary graft failure. 226,235 Successful use of other nondurable devices, including devices from Levitronix and Abiomed, has also been reported for primary graft failure. 226,229 There are few reports specifically addressing use in the setting of AMR.…”

Section: Mechanical Circulatory Support In Amr With Hemodynamic Comprmentioning

confidence: 99%

“…226,235 Successful use of other nondurable devices, including devices from Levitronix and Abiomed, has also been reported for primary graft failure. 226,229 There are few reports specifically addressing use in the setting of AMR. [236][237][238][239] Kittleson and colleagues 239 described the use of ECMO in 32 patients with heart transplant rejection.…”

Section: Mechanical Circulatory Support In Amr With Hemodynamic Comprmentioning

confidence: 99%

See 2 more Smart Citations

Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management

Colvin¹,

Cook²,

Chang³

et al. 2015

Circulation

283

251

View full text Add to dashboard Cite

Section: Mechanical Circulatory Support In Amr With Hemodynamic Comprmentioning

confidence: 99%

Section: Mechanical Circulatory Support In Amr With Hemodynamic Comprmentioning

confidence: 99%

Section: Mechanical Circulatory Support In Amr With Hemodynamic Comprmentioning

confidence: 99%

See 1 more Smart Citation

Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management

Colvin¹,

Cook²,

Chang³

et al. 2015

Circulation

283

251

View full text Add to dashboard Cite

“…Over the following decades, it became an universally accepted method in the treatment of severe forms of heart and respiratory failure in childhood; only in recent years has it become a common treatment modality in adult critical patients [3][4][5] .Thanks to the technical developments and growing experience, the results of ECMO treatment have been increasingly improving, and the indications were gradually extended [6][7][8][9][10] . Consequently, the number of patients treated with ECMO has been growing significantly every year.…”

Section: Način Rada I Osnovni Oblici Ecmo Potporementioning

confidence: 99%

Extracorporeal Membrane Oxygenation in Adults

Bačić

Tomulić

Medved

et al. 2017

Cardiologia Croatica

View full text Add to dashboard Cite

SAŽETAK: Izvantjelesna membranska oksigenacija (engl. Extracorporeal Membrane Oxygenation, ECMO) postupak je izvantjelesne mehaničke cirkulacijske ili respiracijske potpore koji se primjenjuje primarno u bolesnika sa životno ugrožavajućim oblicima zatajivanja rada srca ili pluća. Dva su osnovna oblika ECMO potpore: vensko-venski (V-V) i vensko-arterijski (V-A) ECMO. V-V ECMO osigurava funkciju izmjene plinova u krvi i primjenjuje se u slučaju teške reverzibilne respiracijske insuficijencije. V-A ECMO podržava funkciju rada srca i pluća, a, osim pri reverzibilnim oblicima oštećenja srčane funkcije, može se rabiti i pri njezinu ireverzibilnom oštećenju, kao premoštenje do transplantacije srca ili ugradnje uređaja za mehaničku cirkulacijsku potporu. ECMO je invazivan i tehnički složen postupak koji se obavlja u kritično bolesnih pa stoga nosi visok rizik od pojave komplikacija. Rezultati liječe-nja ECMO-om razlikuju se ovisno o indikaciji za sam postupak. Bolesnici u kojih je ECMO primijenjen radi respiracijske potpore imaju bolje ishode u usporedbi s onima s kardiogenim šokom ili zastojem srca. Iako nedostaju dokazi temeljeni na velikim randomiziranim studijama koji bi poduprli njegovu primjenu, ECMO je u kliničkoj praksi spasonosna metoda liječenja u dobro odabranih, kritičnih bolesnika. SUMMARY:Extracorporeal membrane oxygenation (ECMO) is a procedure that provides extracorporeal mechanical circulatory or respiratory support and is used primarily in patients with life-threatening forms of heart or respiratory failure. There are two basic types of ECMO support: veno-venous (VV) and veno-arterial (VA) ECMO. VV ECMO ensures blood gas exchange and is applied in cases of severe reversible respiratory insufficiency. VA ECMO supports the function of the heart and lungs; other than in reversible forms of damaged heart function, it can also be used in irreversible forms of heart failure as a bridge to heart transplantation or to the implantation of mechanical circulatory support device. ECMO is an invasive and technically complex procedure that is performed in critically ill patients and thus has a high risk of complications. Results of ECMO treatment vary depending on the indications for the procedure itself. Patients in whom ECMO was applied for respiratory support show better outcomes compared with those with cardiogenic shock or cardiac arrest. Despite a lack of evidence based on large randomized studies to support its application, in clinical practice ECMO represents a life-saving method of treatment in well-selected critical patients.KLJUČNE RIJEČI: izvantjelesna membranska oksigenacija, kardiogeni šok, respiracijska insuficijencija.

show abstract

“…The reported incidence and outcomes of PGD have varied markedly among individual centres [3][4][5]6•, 7-10, 11•]. Some of this variability may reflect real differences (possibly reflecting different policies regarding donor and recipient acceptance criteria), but a more likely explanation for the inter-institutional variability is the use of different diagnostic criteria for PGD among centres.…”

Section: Introductionmentioning

confidence: 99%

Primary Graft Dysfunction After Heart Transplantation

et al. 2014

View full text Add to dashboard Cite

Primary graft dysfunction (PGD) is a lifethreatening complication of heart transplantation that presents as left, right, or biventricular dysfunction occurring within the first 24 hours of transplant surgery for which there is no identifiable secondary cause. Myocardial injury caused by acute catecholamine toxicity and the release of multiple proinflammatory mediators in the donor, followed by ischaemiareperfusion injury sustained during retrieval, have been considered the predominant pathogenetic processes leading to PGD. Donor, recipient, and procedural factors contribute to the development and severity of the clinical syndrome. The changing donor and recipient characteristics over the last two decades, particularly the increasing donor and recipient age, have led to heightened risk of PGD. PGD is graded from mild to severe depending on the extent of circulatory support that is required to maintain haemodynamic stability and vital organ function. While advances in acute mechanical support devices have improved the outlook for patients with PGD, the rate of mortality remains high for those with severe PGD, reaching 40 %. Potential approaches to preventing or minimising the severity of PGD include optimising donor management, donor heart preservation, and donor/recipient matching.

show abstract

Early Institution of Mechanical Support Improves Outcomes in Primary Cardiac Allograft Failure

Cited by 100 publications

References 11 publications

Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management

Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management

Extracorporeal Membrane Oxygenation in Adults

Primary Graft Dysfunction After Heart Transplantation

Contact Info

Product

Resources

About